Vanderbilt Clinical Trials

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Purpose

The purpose of the study was to determine the effect of setmelanotide (RM-493) on weight, hunger assessments, and other factors in participants with rare genetic disorders of obesity.

Conditions

Genetic Obesity
Obesity
Obesity Due to Melanocortin 4 Receptor Deficiency

Eligibility

Eligible Ages: Over 6 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Participants with the following genotypes and/or clinical assessment: 1. POMC/PCSK1/LEPR heterozygous - not currently enrolling new participants 2. POMC/PCSK1/LEPR compound heterozygous (two different mutations in gene) or homozygous deficiency obesity 3. POMC/PCSK1/LEPR composite heterozygous (two or more mutations in two or more genes) deficiency obesity 4. SMS 5. SH2B1 deficiency obesity 6. Chromosomal rearrangement of the 16p11.2 locus causing obesity 7. Carboxypeptidase E (CPE) compound heterozygous or homozygous deficiency obesity 8. Leptin deficiency obesity with loss of response to metreleptin 9. SRC1 deficiency obesity 10. MC4R deficiency obesity 2. Age 6 years and above 3. Obese, defined as Body Mass Index (BMI) ≥ 30 kilogram per meter square (kg/m^2) for participants ≥16 years of age or BMI≥ 95th percentile for age and gender for participants 6 up to 16 years of age. 4. Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent 5. Female participants of childbearing potential must be confirmed non-pregnant, and agree to use contraception as outlined in the protocol. 6. Male participants with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study. Male participants must not donate sperm during and for 90 days following their participation in the study.

Exclusion Criteria

Recent intensive (within 2 months) diet and/or exercise regimen with or without the use of weight loss agents that has resulted in > 2% weight loss. 2. Use of any medication that is approved to treat obesity within three months of first dose of study drug (e.g., orlistat, lorcaserin, phentermine-topiramate, naltrexone-bupropion). 3. Gastric bypass surgery within the previous six months or any prior gastric bypass surgery resulting in >10% weight loss durably maintained 4. Diagnosis of schizophrenia, bipolar disorder, personality disorder, major depressive disorder, or other psychiatric disorder(s) 5. Suicidal ideation, attempt or behavior 6. Clinically significant pulmonary, cardiac, or oncologic disease 7. hemoglobin A1c (HbA1c) > 9.0% at Screening 8. History of significant liver disease 9. Glomerular filtration rate (GFR) < 30 milliliter/minute (mL/min) at Screening. 10. History or close family history of melanoma or participant history of oculocutaneous albinism 11. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions. 12. Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing. 13. Participants previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide. 14. Inability to comply with QD injection regimen. 15. Females who are breastfeeding or nursing. Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Phase: Phase 2
Study Type: Interventional
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental 16p11.2 Cohort	Participants with chromosomal rearrangement of the p11.2 region of chromosome 16 (16p11.2) locus causing obesity received setmelanotide once daily (QD) via subcutaneous (SC) injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental AS Cohort	Participants with Alström syndrome (AS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental BBS Cohort	Participants with Bardet-Biedl syndrome (BBS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental MC4R Cohort	Participants with melanocortin-4 receptor (MC4R) deficiency obesity received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental POMC/PCSK1/LEPR Heterozygous Cohort	Participants with pro-opiomelanocortin (POMC)/proprotein convertase subtilisin/kexin type 1 (PCSK1)/leptin receptor (LEPR) heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental POMC/PCSK1/LEPR Composite Heterozygous Cohort	Participants with POMC/PCSK1/LEPR composite heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental POMC/PCSK1/LEPR Compound Heterozygous Cohort	Participants with POMC/PCSK1/LEPR compound heterozygous mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental SH2B1 Cohort	Participants with steroid receptor coactivator (SRC) homology 2B adapter protein 1 (SH2B1) haploinsufficiency received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental SMS Cohort	Participants with Smith-Magenis Syndrome (SMS) received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493
Experimental SRC1 Cohort	Participants with steroid receptor coactivator 1 (SRC1) mutations received setmelanotide QD via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and the dose was escalated up to a maximum dose of 3.0 mg QD. Participants either continued setmelanotide treatment by enrolling in an extension study (RM-493-022; NCT03651765) immediately following the last dose in this study or if the extension study was not open at the current clinic site, participants continued treatment in the current study for up to 1 year, resulting in treatment duration of up to 16 months.	Drug: Setmelanotide RM-493 QD SC injection Other names: RM-493

More Details

Status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.